secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2022-01-04T23:59:59+00:00
Accession:  0001193125-22-001760
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics appoints Esther Rajavelu as CFO and Treasurer
------------------------------------------------------------------

- Esther Rajavelu appointed CFO and Treasurer effective Jan 3, 2022; Peter Thomson ceases as principal financial officer.
- Rajavelu receives $435,000 annual base salary, $150,000 signing bonus, and 200,000 stock option at $17.82/share.
- Option vests 25% on first anniversary, then 6.25% quarterly over 12 quarters.
- Rajavelu has ~20 years life sciences experience including UBS, Oppenheimer, Deutsche Bank, and EY Capital.
- Press release highlights two disease-modifying programs (losmapimod for FSHD, FTX-6058 for sickle cell).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/0001193125-22-001760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312522001760/d237013d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-001760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer